See the DrugPatentWatch profile for Saxenda
Saxenda is a prescription medication used for chronic weight management in adults with obesity or overweight with at least one weight-related condition [1]. The National Drug Code (NDC) for a 3 mL pen of Saxenda is not a single, universally fixed number and can vary based on factors such as the manufacturer, pack size, and specific formulation or labeling at the time of dispensing [2].
What is the NDC for Saxenda?
The NDC is a unique 10- or 11-digit number used in the United States to identify drug products [2]. It consists of three segments: the first identifies the labeler (manufacturer, packager, or distributor), the second identifies the product, and the third identifies the package size [2]. Because Saxenda is available in different presentations, such as single pens or multi-packs, and through different suppliers, its NDC may differ [2]. For the most precise NDC for a specific Saxenda 3 mL pen, it is recommended to check the product packaging or consult with a pharmacist [2].
How does Saxenda work for weight management?
Saxenda contains the active ingredient liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. Liraglutide mimics the action of the natural GLP-1 hormone, which helps regulate appetite by affecting areas in the brain that control hunger and fullness [1][3]. This can lead to reduced food intake and subsequent weight loss when used in conjunction with a reduced-calorie diet and increased physical activity [1].
What are the different strengths and dosages of Saxenda?
Saxenda is administered as a subcutaneous injection once daily [1]. The typical maintenance dose is 3 mg once daily [1]. The dose is usually started at a lower level and gradually increased over several weeks to reach the target maintenance dose, helping to minimize gastrointestinal side effects [1]. The 3 mL pen is designed to deliver these doses, with the pen containing a total of 18 mg of liraglutide [4].
When does the patent for Saxenda expire?
The patent protection for drugs like Saxenda plays a significant role in market exclusivity and the potential introduction of generic alternatives. Information regarding the specific patent expiry dates for Saxenda can be found through specialized resources that track pharmaceutical patents [5]. These patents typically cover the active ingredient, manufacturing processes, and specific formulations.
Who manufactures Saxenda?
Saxenda is manufactured by Novo Nordisk, a global healthcare company [1][6]. Novo Nordisk is known for its work in diabetes care and also develops treatments for other serious chronic diseases [6].
What are the common side effects of Saxenda?
The most common side effects associated with Saxenda treatment include nausea, diarrhea, constipation, vomiting, abdominal pain, headache, fatigue, dizziness, and dry mouth [1]. These side effects are often dose-dependent and tend to decrease over time as the body adjusts to the medication [1]. More serious side effects, though less common, can include pancreatitis, gallbladder problems, kidney issues, and an increased heart rate [1].
Can Saxenda be used with other weight management medications?
Saxenda is intended for use as a standalone treatment for chronic weight management, combined with a healthy diet and exercise [1]. It is not typically recommended for use in combination with other liraglutide-containing products or other GLP-1 receptor agonists [1]. The decision to prescribe Saxenda and manage its use, including potential interactions with other medications, is made by a healthcare professional based on an individual patient's health profile [1].
How is Saxenda administered?
Saxenda is administered via subcutaneous injection, meaning it is injected into the fatty tissue just under the skin [1]. It can be injected into the abdomen, thigh, or upper arm [1]. Patients are instructed on proper injection technique, including how to use the pen device and change needles for each injection to ensure safety and effectiveness [1].
Sources:
[1] https://www.saxenda.com/
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
[3] https://www.drugpatentwatch.com/
[4] https://www.novo-pi.com/saxenda.html
[5] https://www.drugpatentwatch.com/
[6] https://www.novonordisk.com/